Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Colon Cancer Forum

Reply
 
Thread Tools Display Modes
  #1  
Old 11-29-2010, 09:45 AM
Dross Dross is offline
Moderator
 
Join Date: Nov 2006
Posts: 883
Default Dartmouth Study Uses the Patient's Tumor to Form Vaccine

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published in the journal Clinical Cancer Research, was used after surgical resection of metastatic tumors to try to prevent the growth of additional metastases.

"The results of the study suggest a new way to approach cancer treatment," said Richard Barth Jr., MD, Chief of General Surgery at Dartmouth-Hitchcock Medical Center and a member of the Gastrointestinal Clinical Oncology Group at Dartmouth-Hitchcock Norris Cotton Cancer Center, who is the study's principal investigator. "Basically, we've worked out a way to use dendritic cells, which initiate immune responses, to induce an antitumor response."

[url]http://cancer.dartmouth.edu/doctor_search/profile/469/Richard_J_Barth_Jr._MD

Last edited by gdpawel : 02-14-2012 at 11:58 PM. Reason: correct url address
Reply With Quote
  #2  
Old 06-20-2012, 08:25 AM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,345
Default Dendritic Cell Function in Cancer

Another approach to cancer therapy takes advantage of the normal role of the dendritic cell as an immune educator. Dendritic cells grab antigens from viruses, bacteria, or other organisms and wave them at T cells to recruit their help in an initial T cell immune response. This works well against foreign cells that enter the body, but cancer cells often evade the self/non-self detection system. By modifying dendritic cells, researchers are able to trigger a special kind of autoimmune response that includes a T cell attack of the cancer cells. Because a cancer antigen alone is not enough to rally the immune troops, scientists first fuse a cytokine to a tumor antigen with the hope that this will send a strong antigenic signal. Next, they grow a patient's dendritic cells in the incubator and let them take up this fused cytokine-tumor antigen. This enables the dendritic cells to mature and eventually display the same tumor antigens as appear on the patient's cancer cells. When these special mature dendritic cells are given back to the patient, they wave their newly acquired tumor antigens at the patient's immune system, and those T cells that can respond mount an attack on the patient's cancer cells.

[url]http://www.cancer.gov/cancertopics/understandingcancer/immunesystem/page34
__________________
Gregory D. Pawelski
Reply With Quote
  #3  
Old 06-20-2012, 09:04 AM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,345
Default Dendritic cells and immunity against cancer

From the Baylor Institute for Immunology Research and Sammons Cancer Center, Baylor University MedicalCenter, Dallas, TX; and Department of Gene and Cell Medicine and Department of Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, NY, USA

T cells can reject established tumours when adoptively transferred into patients, thereby demonstrating the power of the immune system for cancer therapy.

However, it has proven difficult to maintain adoptively transferred T cells in the long term. Vaccines have the potential to induce tumour-specific effector and memory T cells.

However, clinical efficacy of current vaccines is limited, possibly because tumours skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells.

To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumour microenvironment.

This can be achieved by exploiting the fast increasing knowledge about the dendritic cell (DC) system, including the existence of distinct DC subsets that respond differentially to distinct activation signals, (functional plasticity), both contributing to the generation of unique adaptive immune responses.

We foresee that these novel cancer vaccines will be used as monotherapy in patients with resected disease and in combination with drugs targeting regulatory ⁄ suppressor pathways in patients with metastatic disease.

[url]http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2010.02317.x/pdf
__________________
Gregory D. Pawelski
Reply With Quote
Sponsored Links
Advertisement
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 11:26 PM.